When the Pressure is High the Dementia is Low
Sounds of Science Podcast
Tuning Up or Taming Immune Responses
New Immunotherapeutic Strategies Include Bispecific Antibodies, Engineered Adenoviruses, and Specifically Formulated Vaccines against Cancer
The Promise of Tumor Mutational Burden for Cancer Immunotherapy
Quantitative Biomarkers Could Be the Next Step for Precision Oncology
Just Enough Downstream Innovation
Downstream Operations Can Relieve the Pressure of Higher Titers and Cell Densities without Undue Disruption
For full access to this article login to GEN Select now.
Fine-Tuning Cell-Based Assays
- Years of research and untold costs of development are wasted when a drug is withdrawn from the market. Pharmaceutical companies go to great lengths to prevent such loss, carrying out exhaustive studies from the preclinical phase through late-stage clinical trials to identify problems and eliminate them early. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.